|
Thailand Law Journal 2009 Spring Issue 1 Volume 12The purpose of this paper has been to articulate a framework through which to understand the imperative of product development public-private partnerships. However, I have left many questions to be addressed. First, it is unclear how organizational structure may interact with strategy to overcome public and private failures. Second, though I have discussed the cultural differences between public and private organizations, I have not attempted to evaluate cultural dynamics in existing PPPs. Perhaps most importantly, more work must be done to determine how to ex ante apportion the rights and responsibilities associated with drug development projects from early discovery to developing country distribution. Early PD-PPP literature has tended to originate from the ranks of high-profile partnerships like TDR, MMV, and IAVI. Involved parties must continue to discuss innovative approaches to these and other problems so that the effectiveness of current PPPs is maximized. As a society, we cannot afford to misuse the scarce funds available for the innovation of new drugs for neglected diseases. List of Abbreviations
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is published with the kind permission of Nathaniel Lipkus. The article originally appeared in Michigan State University Journal of Medicine & Law, Spring 2006 issue. |
©
Copyright Thailand Law Forum, All Rights Reserved
(except where the work is the individual works of the authors as noted)